WuXi AppTec subsidiary, STA Pharmaceutical (WuXi STA), has opened its large-scale oligonucleotide active pharmaceutical ingredient (API) manufacturing facility in Changzhou, China.
This significant milestone marks WuXi STA’s establishment of a comprehensive one-stop platform to support the process R&D and manufacture of oligonucleotide APIs from preclinical to commercial.
It enables customers around the world to advance promising new oligonucleotide therapies more rapidly to market for the benefit of patients.
The new facility, with over 30,000 sq ft, is located at WuXi STA’s Changzhou site. With its operation, the Changzhou site can manufacture oligonucleotide APIs up to 1 mol/synthesis run, to better meet the increasing demand of our customers.
“By leveraging our small-molecule CMC (Chemical, Manufacturing, and Control) technology and capability platform as well as global standard quality system, WuXi STA provides a robust one-stop shop for oligonucleotide innovators,” said Dr. Minzhang Chen, CEO of WuXi STA.
“The opening of this large scale manufacturing facility will empower more global partners to expedite the development and commercialization of oligonucleotide drugs to benefit patients worldwide.”